Last updated: 18 March 2022 at 9:01pm EST

Capital, Llc Boxer Asset Ma... Net Worth




The estimated Net Worth of Capital, Llc Boxer Asset Ma... is at least $78.8 million dollars as of 17 March 2022. Capital Ma owns over 575,201 units of iTeos Therapeutics stock worth over $50,241,507 and over the last 7 years Capital sold ITOS stock worth over $28,597,835.

Capital Ma ITOS stock SEC Form 4 insiders trading

Capital has made over 13 trades of the iTeos Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital sold 575,201 units of ITOS stock worth $20,275,835 on 17 March 2022.

The largest trade Capital's ever made was buying 1,403,509 units of iTeos Therapeutics stock on 28 August 2020 worth over $20,000,003. On average, Capital trades about 398,496 units every 120 days since 2017. As of 17 March 2022 Capital still owns at least 3,142,058 units of iTeos Therapeutics stock.

You can see the complete history of Capital Ma stock trades at the bottom of the page.



Insiders trading at iTeos Therapeutics

Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol... et Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.



What does iTeos Therapeutics do?

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.



What does iTeos Therapeutics's logo look like?

iTeos Therapeutics, Inc. logo

Complete history of Capital Ma stock trades at Esperion Therapeutics, Mirati Therapeutics Inc, Odonate Therapeutics Inc et iTeos Therapeutics

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
17 Mar 2022 Capital, Llc Boxer Asset Ma...
Vente 575,201 $35.25 $20,275,835
17 Mar 2022
3,142,058
22 Nov 2021 Capital, Llc Boxer Asset Ma...
Vente 400,000 $1.56 $624,000
22 Nov 2021
4,207,086
17 Nov 2021 Capital, Llc Boxer Asset Ma...
Vente 1,000,000 $2.06 $2,060,000
17 Nov 2021
4,607,086
28 Dec 2020 Capital, Llc Boxer Asset Ma...
Acheter 400,000 $17.16 $6,864,000
28 Dec 2020
5,607,086
28 Sep 2020 Capital, Llc Boxer Asset Ma...
Acheter 215,200 $13.63 $2,933,176
28 Sep 2020
5,207,086
4 Sep 2020 Capital, Llc Boxer Asset Ma...
Acheter 225,000 $14.99 $3,372,750
4 Sep 2020
4,991,886
28 Aug 2020 Capital, Llc Boxer Asset Ma...
Acheter 1,403,509 $14.25 $20,000,003
28 Aug 2020
4,766,886
21 Dec 2018 Capital, Llc Boxer Asset Ma...
Acheter 125,000 $13.27 $1,658,750
21 Dec 2018
2,978,762
24 Oct 2018 Capital, Llc Boxer Asset Ma...
Acheter 26,824 $14.72 $394,849
24 Oct 2018
2,853,762
22 Mar 2018 Capital, Llc Boxer Asset Ma...
Acheter 100,000 $22.73 $2,273,000
22 Mar 2018
2,826,938
6 Dec 2017 Capital, Llc Boxer Asset Ma...
Acheter 416,666 $24.00 $9,999,984
6 Dec 2017
2,726,938
2 Nov 2018 Capital, Llc Boxer Asset Ma...
Vente 100,000 $56.38 $5,638,000
2 Nov 2018
1,101,250
7 Jun 2018 Capital, Llc Boxer Asset Ma...
Acheter 193,050 $38.85 $7,499,993
7 Jun 2018
1,565,560


iTeos Therapeutics executives and stock owners

iTeos Therapeutics executives and other stock owners filed with the SEC include: